Mike Nuñez Pfzr

Husband,Dad,🐊 Grad/Fan.Pfizer FL Hematology. 🇺🇸🇨🇺. opinions are my own

[Eddie Nunez @EddieNunezAD]

Coog Nation-One of the Toughest and Unbreakable Coogs! Please help support Kurt in his fight.
Thank you!

[C. Ola Landgren, M.D. @DrOlaLandgren]

NEW STUDY ONLINE Tocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific Antibodies

#mmsm ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@HealthTree⁩ ⁦@ASH_hematology⁩ ⁦@SylvesterCancer⁩ ⁦@univmiami⁩ https://t.co/ud0braQ160

[Eddie Nunez @EddieNunezAD]

Check out our Coogs making a difference at the Capitol yesterday.

[Dolphins Cancer Challenge @TackleCancer]

10 days till the big day and $7 million raised for @SylvesterCancer 🤩

[Houston Athletics @UHCougars]

Locked in! 🫡

#GoCoogs x @EddieNunezAD

[FLASCO @FLASCO_ORG]

Moderator @ChaulagainMD kicks off
“How to Best Integrate Newly Approved Bi-Specific Monoclonal Antibodies and CAR-T Cell Therapy in Myeloma” with panelists Saffet Guleryuz, MD, Ciara Freeman, MD, Arlene Gayle, MD, & Sikander Ailawadhi, MD

#FLASCO #BOSS2024 #MultipleMyeloma

[Mike Nuñez Pfzr @MikeNunezOnc]

@app1279 Dale que se puede

[Mike Nuñez Pfzr @MikeNunezOnc]

@app1279 That’s priceless

[Pfizer Oncology Medical @PfizerOncMed]

In @NatureMedicine, see results from the phase 2 MagnetisMM-3 trial evaluating the efficacy and safety of a BCMA-CD3 bispecific antibody in patients with relapsed/refractory #MultipleMyeloma

[Mike Nuñez Pfzr @MikeNunezOnc]

Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma - https://t.co/V2EFv0M5OW

[C. Ola Landgren, M.D. @DrOlaLandgren]

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

This podcast summarizes T cell–redirecting BsAb currently in development for relapsed/refractory MM with a focus on the data reported at ASH22 oral session https://t.co/SHkSSm37z1

[New Mexico Lobos @UNMLOBOS]

Congrats to the big boss on this prestigious appointment!!! #GoLobos

https://t.co/3FC6PXyAw2

[Pfizer Medical @PfizerMed]

Calling all HCPs! We are now accepting applications for our Quality Improvement competitive grant to support the development of emerging cardiac amyloid centers in areas of higher need. Don't miss out. Apply by July 20th!

#ATTRCM #HealthcareDisparities

[C. Ola Landgren, M.D. @DrOlaLandgren]

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

@OmarNadeemMD
⁦@springerlink⁩ ⁦@theMMRF⁩ ⁦@IMFmyeloma⁩ #mmsm ⁦@HealthtreeMM⁩ ⁦⁩@SylvesterCancer⁩ https://t.co/BSH044QWTG

[OncLive.com @OncLive]

BREAKING: @US_FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC #pcsm #oncology https://t.co/MledN8OS38

[Kara Mondy @Kara_Pfizer]

Attending the 1st Annual Precisca Fellows Forum and Faculty Retreat. What a great opportunity to learn alongside oncology fellows from top institutions across the country #PreciscaFellowsForum #mmsm

[Pfizer Medical @PfizerMed]

#PfizerMedInfo provides access to helpful resources for Pfizer products including a temperature stability calculator, allergen/ingredient checker and drug interaction tool.

[Mike Nuñez Pfzr @MikeNunezOnc]

I donated in support of Dolphins Challenge Cancer! https://t.co/1zyeHqJiX5

[Mike Nuñez Pfzr @MikeNunezOnc]

I donated in support of Dolphins Challenge Cancer! https://t.co/d8EwU2neNt

[Erinn Goldman @DrErinnGoldman]

Proud to be an author on this long-term analysis of patients with CML